Close the 2021 royalty, license and termination agreement with Takeda
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Mar 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Expect closing at the end of Q1 2021, subject to customary closing conditions”
What we found
Evidence strength A What the grades mean
The Q1 2021 10-Q says the Takeda agreement was entered in March 2021 and the $196.0 million upfront payment had been received as of March 31, 2021, indicating closing by the deadline.
-
A Ovid Therapeutics Inc. 10-Q filed 2021-05-13
“In March 2021, we entered into a royalty, license and termination agreement (“Takeda License and Termination Agreement”) with Takeda” ✓ confirmed on the page
-
A Ovid Therapeutics Inc. 10-Q filed 2021-05-13
“a one-time, upfront payment of $196.0 million received pursuant to the Company’s royalty, license and termination agreement” ✓ confirmed on the page
-
A Ovid Therapeutics Inc. 10-Q filed 2021-05-13
“During the three months ended March 31, 2021, we generated $208.4 million of license and other revenue through our Collaboration and License Agreement” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Close
- Deliverable
- Closing of the 2021 royalty, license and termination agreement with Takeda
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to customary closing conditions; subject to regulatory approvals
- Depends on
- Counterparty, Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Ovid Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-OVID-025089 · Corrections policy